... antibody approved for the treatment of B-cell non-Hodgkin lymphoma (NHL) expressing CD20 antigen. This antibody has also the potential to be used as a specific fluorescent and radiolabel agent for targeting NHL. Objective: To radiolabel rituximab with technetium-99m ( 99m Tc) or Cy7 and evaluate both...

...Li Wu; Tong Wang; Wei Gui; Hualiang Lin; Kaipeng Xie; Hui Wang; Tao Gao; Xiuxiu Zhang; Lei Liu; Ting Han; Yuan Tian; Lifang Hou Background and Objective: Elevated serum beta-2 microglobulin (β2-M) has previously been reported in non-Hodgkin lymphoma (NHL) patients. This study examined...

...). The studies were performed on 48 patients with untreated non-Hodgkin lymphoma, 14 Hodgkin patients, 5 patients with lymphadenitis and on 132 controls. In the control group the following percentages of B-T lymphocytes were obtained: blood (n=100): T-68 ± 9, B-20 ± 6, 0-11 ± 7, BT-1 + 1, lymph nodes (n=24): T...

...) with CEOP, a CHOP-like regimen (cyclophosphamide, epirubicin, vincristine and prednisone), in elderly patients (≧65 years) with aggressive non-Hodgkin’s lymphoma (NHL). Methods: One hundred and forty-nine patients were eligible, 72 in the MEMID arm and 77 in the CEOP arm. The primary endpoint was to compare...